Scribe Therapeutics (SCTX) News
NASDAQ: SCTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SCTX news summary
We found 5 recent headlines mentioning Scribe Therapeutics (SCTX): 2 in the past week and 3 in the past 30 days, most often from Nasdaq, GlobeNewswire. SCTX is making an outsized move today, down 8.70% at $12.07, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Scribe Therapeutics Reports Long-Lasting Cholesterol Reduction And Promising Lp(a) Data", was published by Nasdaq on Nov 18, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Scribe Therapeutics headlines
- Scribe Therapeutics Reports Long-Lasting Cholesterol Reduction And Promising Lp(a) Data(RTTNews) - Scribe Therapeutics Inc. (SCTX) presented new preclinical data from its STX-1150 and STX-1200 programs at the American Heart Association (AHA) Scientific Sessions 2026, highlighting the…NasdaqSCTX, HEI.A
- Scribe Therapeutics Presents New Data Advancing the Potential of Ultra-Long-Acting Genetic Medicines for Cardiovascular Disease at AHA Scientific Sessions 2026Scribe Therapeutics presents new data advancing the potential of ultra-long-acting genetic medicines for cardiovascular disease at AHA Scientific SessionsGlobeNewswire
- Cathie Wood Bought Just 3 Stocks On Monday; Here They AreKey PointsCathie Wood bought shares in Nvidia, SoFi, and Scribe Therapeutics on Monday.NasdaqNVDA, SCTX, SOFI
- Cathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtKey PointsCathie Wood's Ark Invest bought shares of CoreWeave, Scribe Therapeutics, and Freenome on Monday.NasdaqCRWV, FRNM, SCTX
- Biotech Stocks At 52-Week Highs - SCTX Continues Rise After Nasdaq Debut, RPRX, HAE, TXG, LH(RTTNews) - The following biotech stocks reached a 52-week high on August 20, 2026, driven by key catalysts such as new product launches and the prospective release of data from clinical studies.NasdaqHAE, LH, RPRX, SCTX